Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
SanofiNASDAQ: SNY
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) declines year over year
Q2 FY2026 EPS (Diluted) of €0.14 fell 91.3% year over year, behind the -87.2% change in trailing-twelve-month EPS (Diluted). Sequentially, it fell 79.1% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- EPS (Diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of €4.11 (+28.6%) for the fiscal year ending Dec 2026, a slowdown from the +46.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- €0.14-79.1% QoQ
- Last fiscal yearDec 2025
- €3.2+46.1% YoY
- LTMJun 2026
- €0.49-87.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -91.3% | +23.1% | +114.4 pp |
| 1 year | +46.1% | +28.6% | -17.6 pp |
| 3-year CAGR | +0.2% | +13.9% | +13.7 pp |
| 5-year CAGR | +11.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
EUR · from the income statement
- Latest · FY2025
- 3.20 EUR
- Year-over-year change
- +46.1%
- 4-year CAGR
- +6.5%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.20 | +46.1% |
| FY2024 | 2024-12-31 | 2.19 | +1.9% |
| FY2023 | 2023-12-31 | 2.15 | -32.4% |
| FY2022 | 2022-12-31 | 3.18 | +27.7% |
| FY2021 | 2021-12-31 | 2.49 | — |
EPS (Diluted) vs competitors
How SNY compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -87.2% is the 10th highest of 11, against a peer median of +10.7%.
- Over three fiscal years its annual growth of +0.2% compares with a peer median of +15.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $29.8 USD | +94.8% | +51.7% | |
| LTM Jun 2026 | DKK 26.19 DKK | +5.0% | +23.5% | |
| LTM Jun 2026 | $16.09 USD | +31.6% | +5.5% | |
| LTM Sep 2026 | $7.01 USD | +16.4% | +45.8% | |
| LTM Jun 2026 | $6.63 USD | -3.4% | +31.4% | |
| LTM Jun 2026 | $4.54 USD | +83.4% | +5.4% | |
| LTM Jun 2026 | £2.37 GBP | +43.5% | -27.6% | |
| LTM Jun 2026 | $1.25 USD | -80.7% | +8.4% | |
| LTM Jun 2026 | $0.76 USD | -59.9% | -37.1% | |
| LTM Jun 2026 | €0.49 EUR | -87.2% | +0.2% | |
| LTM Jun 2026 | -$2.67 USD | -153.2% | +23.0% | |
| Peer median (excluding SNY) | — | +10.7% | +15.7% | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.18B | 40.56B | 41.62B | 44.29B | 46.72B |
| Cost of Revenue | 12.26B | 11.88B | 12.63B | 13.21B | 13.05B |
| Gross Profit | 26.92B | 28.68B | 28.99B | 31.08B | 33.67B |
| Gross Margin | 68.7% | 70.7% | 69.7% | 70.2% | 72.1% |
| Research & Development | 5.69B | 6.5B | 6.51B | 7.39B | 7.84B |
| Selling, General & Admin | 9.56B | 8.74B | 8.93B | 9.18B | 10.24B |
| Operating Expenses | 18.79B | 18.52B | 22.03B | 23.83B | 24.07B |
| Depreciation & Amortization | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| EBITDA | 11.54B | 13.51B | 11.39B | 11.03B | 12.48B |
| EBITDA Margin | 29.5% | 33.3% | 27.4% | 24.9% | 26.7% |
| Operating Income | 8.13B | 10.16B | 6.96B | 7.25B | 9.6B |
| Operating Margin | 20.7% | 25.1% | 16.7% | 16.4% | 20.5% |
| Interest Income | 3.13M | 168.96M | 530.5M | 457.53M | 331M |
| Interest Expense | 377.37M | 384.8M | 512.82M | 622.58M | 626M |
| Other Income / Expenses | (289M) | (170M) | (845M) | (494M) | (3.58B) |
| Income Before Tax | 7.84B | 9.99B | 6.12B | 6.76B | 6.02B |
| Pre-Tax Margin | 20.0% | 24.6% | 14.7% | 15.3% | 12.9% |
| Income Tax Expense | 1.56B | 1.91B | 1.02B | 1.2B | 1.04B |
| Net Income | 6.22B | 8.37B | 5.4B | 5.56B | 7.81B |
| Net Margin | 15.9% | 20.6% | 13.0% | 12.6% | 16.7% |
| EPS (Basic) | 2.49 | 3.19 | 2.15 | 2.19 | 3.20 |
| EPS (Diluted) | 2.49 | 3.18 | 2.15 | 2.19 | 3.20 |
| Weighted Avg Shares | 2.51B | 2.5B | 2.5B | 2.5B | 2.44B |
| Weighted Avg Shares (Diluted) | 2.51B | 2.5B | 2.51B | 2.5B | 2.44B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.